Coronavirus Antibody Responses before COVID-19 Pandemic, Africa and Thailand.

Africa COVID-19 HIV-1 SARS SARS-CoV-2 Thailand coronavirus coronavirus disease respiratory infections serosurvey severe acute respiratory syndrome coronavirus 2 viruses zoonoses

Journal

Emerging infectious diseases
ISSN: 1080-6059
Titre abrégé: Emerg Infect Dis
Pays: United States
ID NLM: 9508155

Informations de publication

Date de publication:
11 2022
Historique:
pubmed: 12 10 2022
medline: 28 10 2022
entrez: 11 10 2022
Statut: ppublish

Résumé

Prior immune responses to coronaviruses might affect human SARS-CoV-2 response. We screened 2,565 serum and plasma samples collected from 2013 through early 2020, before the COVID-19 pandemic began, from 2,250 persons in 4 countries in Africa (Kenya, Nigeria, Tanzania, and Uganda) and in Thailand, including persons living with HIV-1. We detected IgG responses to SARS-CoV-2 spike (S) subunit 2 protein in 1.8% of participants. Profiling against 23 coronavirus antigens revealed that responses to S, subunit 2, or subunit 1 proteins were significantly more frequent than responses to the receptor-binding domain, S-Trimer, or nucleocapsid proteins (p<0.0001). We observed similar responses in persons with or without HIV-1. Among all coronavirus antigens tested, SARS-CoV-2, SARS-CoV-1, and Middle East respiratory syndrome coronavirus antibody responses were much higher in participants from Africa than in participants from Thailand (p<0.01). We noted less pronounced differences for endemic coronaviruses. Serosurveys could affect vaccine and monoclonal antibody distribution across global populations.

Identifiants

pubmed: 36220131
doi: 10.3201/eid2811.221041
pmc: PMC9622245
doi:

Substances chimiques

Antibodies, Monoclonal 0
Antibodies, Viral 0
Immunoglobulin G 0
Nucleocapsid Proteins 0
Spike Glycoprotein, Coronavirus 0
spike protein, SARS-CoV-2 0

Types de publication

Journal Article Research Support, U.S. Gov't, Non-P.H.S. Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2214-2225

Subventions

Organisme : NIAID NIH HHS
ID : AAI20052001
Pays : United States

Références

J Immunol Methods. 2020 Dec;487:112874
pubmed: 33022219
Virus Evol. 2021 Feb 05;7(1):veab007
pubmed: 33754082
Nat Commun. 2021 Nov 18;12(1):6703
pubmed: 34795285
NPJ Vaccines. 2022 Feb 28;7(1):28
pubmed: 35228535
EBioMedicine. 2021 Dec;74:103700
pubmed: 34861490
J Clin Microbiol. 2021 Jun 18;59(7):e0051421
pubmed: 33853839
Viruses. 2022 Jan 09;14(1):
pubmed: 35062318
Cell. 2021 Apr 1;184(7):1858-1864.e10
pubmed: 33631096
mBio. 2020 Sep 25;11(5):
pubmed: 32978311
Trop Med Int Health. 2021 Jun;26(6):621-631
pubmed: 33666297
Emerg Infect Dis. 2022 Feb;28(2):440-444
pubmed: 35076009
AIDS. 2021 Sep 1;35(11):1872-1874
pubmed: 33993131
Emerg Infect Dis. 2021 Jan;27(1):
pubmed: 33261717
Lancet HIV. 2022 May;9(5):e323-e331
pubmed: 35338835
Sci Immunol. 2021 Oct 15;6(64):eabj2901
pubmed: 34652962
Proc Natl Acad Sci U S A. 2021 Sep 21;118(38):
pubmed: 34470866
J Immunol Methods. 2021 Oct;497:113104
pubmed: 34303688
MMWR Morb Mortal Wkly Rep. 2022 Mar 11;71(10):375-377
pubmed: 35271558
Clin Immunol. 2021 Aug;229:108782
pubmed: 34118402
Front Immunol. 2022 Apr 27;13:856033
pubmed: 35585976
J Immunol Methods. 2011 Mar 7;366(1-2):8-19
pubmed: 21192942
Microbiol Spectr. 2021 Sep 3;9(1):e0013421
pubmed: 34319133
Science. 2020 Nov 27;370(6520):
pubmed: 32994364
Microbiol Resour Announc. 2019 Jul 11;8(28):
pubmed: 31296683
Clin Microbiol Infect. 2021 Dec;27(12):1851-1855
pubmed: 34438069
Cell Host Microbe. 2022 Sep 14;30(9):1269-1278.e4
pubmed: 35932763
EClinicalMedicine. 2022 Jan;43:101226
pubmed: 34901799
Int J Infect Dis. 2020 Dec;101:191-193
pubmed: 33002616
Nature. 2022 Mar;603(7903):913-918
pubmed: 35114688
N Engl J Med. 2021 Aug 5;385(6):562-566
pubmed: 34347959
Int J Infect Dis. 2021 Jan;102:118-122
pubmed: 33075535
Int J Infect Dis. 2021 Jan;102:577-583
pubmed: 33176202
Nat Commun. 2021 May 19;12(1):2938
pubmed: 34011939
PLoS Pathog. 2022 Sep 22;18(9):e1010828
pubmed: 36136995

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH